Spot on Tech and CT...the May 5 preprint and the T
Post# of 155533
(Total Views: 719)
Posted On: 11/10/2020 5:33:01 PM
Spot on Tech and CT...the May 5 preprint and the Ted Talk in layman's terms are all of this is part of the reason I'm so salty lately. You can say I don't have a right to, and that we'll eventually get there, but we had this- I mean I was convinced we really had it in the bag. As CT said, "Patterson described the cure and gift wrapped it". This was over 6 months ago. Nevermind many investors lost a small fortune, the world lost hundreds of thousands of people that may have benefited and ultimately saved.
So why have we not advanced with a superior product while others have? Everyone here wants to blame some FDA grand conspiracy. Did they hold us down, or did we not give them what they needed? I'm a big believer in accountability in the business world. IMO, it's inexperience, incompetence, refusal to collaborate with BP partners, or all of the above. Somebody didn't execute on some level, and if you ask me, I'd wager strongly that the buck stops at the top. If that is the case, and we did indeed fail/fall behind with a superior product, what makes you believe something will change with other indications. We already know what it can do for HIV and can't get a BLA accepted coming up on 3 years from hitting the P3 primary endpoint. And despite all the claims of a dozen trials ready to go at the end of this year, we really only have 3 people in the TNBC trial and we're short of the 75% interim in CD12. That's it. The rest are on the shelf while the financial situation deteriorates. I want to and do believe we have a remarkable product, but I see superior products with poor business execution lose every day in the real world.
So why have we not advanced with a superior product while others have? Everyone here wants to blame some FDA grand conspiracy. Did they hold us down, or did we not give them what they needed? I'm a big believer in accountability in the business world. IMO, it's inexperience, incompetence, refusal to collaborate with BP partners, or all of the above. Somebody didn't execute on some level, and if you ask me, I'd wager strongly that the buck stops at the top. If that is the case, and we did indeed fail/fall behind with a superior product, what makes you believe something will change with other indications. We already know what it can do for HIV and can't get a BLA accepted coming up on 3 years from hitting the P3 primary endpoint. And despite all the claims of a dozen trials ready to go at the end of this year, we really only have 3 people in the TNBC trial and we're short of the 75% interim in CD12. That's it. The rest are on the shelf while the financial situation deteriorates. I want to and do believe we have a remarkable product, but I see superior products with poor business execution lose every day in the real world.
(10)
(0)